P. Juin, O. Geneste, F. Gautier, S. Depil, and M. Campone, Decoding and unlocking the BCL-2 dependency of cancer cells, Nat Rev Cancer, vol.13, pp.455-65, 2013.

J. Montero and A. Letai, Why do BCL-2 inhibitors work and where should we use them in the clinic?, Cell Death Differ, vol.25, pp.56-64, 2018.

S. Kumar, J. L. Kaufman, C. Gasparetto, J. Mikhael, R. Vij et al., Efficacy of venetoclax as targeted therapy for relapsed/ refractory t(11;14) multiple myeloma, Blood, vol.130, pp.2401-2410, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01631468

B. Perillo, A. Sasso, C. Abbondanza, and G. Palumbo, 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence, Mol Cell Biol, vol.20, pp.2890-901, 2000.

C. Curtis, S. P. Shah, S. Chin, G. Turashvili, O. M. Rueda et al., The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups, Nature, vol.486, pp.346-52, 2012.

S. R. Oakes, F. Vaillant, E. Lim, L. Lee, K. Breslin et al., Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737, Proc Natl Acad Sci USA, vol.109, pp.2766-71, 2012.

K. Louault,

F. Vaillant, D. Merino, L. Lee, K. Breslin, B. Pal et al., Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer, Cancer Cell, vol.24, pp.120-129, 2013.

M. F. Van-delft, A. H. Wei, K. D. Mason, C. J. Vandenberg, L. Chen et al., The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized, Cancer Cell, vol.10, pp.389-99, 2006.

A. Qiao, F. Gu, X. Guo, X. Zhang, and L. Fu, Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications, Front Med, vol.10, pp.33-40, 2016.

S. Winslow, K. Leandersson, A. Edsjö, and C. Larsson, Prognostic stromal gene signatures in breast cancer, Breast Cancer Res BCR, vol.17, p.23, 2015.

P. Sansone, M. Berishaj, V. K. Rajasekhar, C. Ceccarelli, Q. Chang et al., Evolution of cancer stem-like cells in endocrineresistant metastatic breast cancers Is mediated by stromal microvesicles, Cancer Res, vol.77, pp.1927-1968, 2017.

A. Marusyk, D. P. Tabassum, M. Janiszewska, A. E. Place, A. Trinh et al., Spatial proximity to fibroblasts impacts molecular features and therapeutic Sensitivity of breast cancer cells influencing clinical outcomes, Cancer Res, vol.76, pp.6495-506, 2016.

P. Gascard and T. D. Tlsty, Carcinoma-associated fibroblasts: orchestrating the composition of malignancy, Genes Dev, vol.30, pp.1002-1021, 2016.

H. Denys, L. Derycke, A. Hendrix, W. Westbroek, A. Gheldof et al., Differential impact of TGF-beta and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion, Cancer Lett, vol.266, pp.263-74, 2008.

D. L. Holliday and V. Speirs, Choosing the right cell line for breast cancer research, Breast Cancer Res BCR, vol.13, p.215, 2011.

Y. Xiao, P. Nimmer, G. S. Sheppard, M. Bruncko, P. Hessler et al., MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor, Mol Cancer Ther, vol.14, pp.1837-1884, 2015.

P. Sansone, G. Storci, S. Tavolari, T. Guarnieri, C. Giovannini et al., IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland, J Clin Invest, vol.117, pp.3988-4002, 2007.

C. Leu, F. Wong, C. Chang, S. Huang, and C. Hu, Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways, Oncogene, vol.22, pp.7809-7827, 2003.

C. Dousset, S. Maïga, P. Gomez-bougie, L. Coq, J. Touzeau et al., BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma, Br J Haematol, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01353369

J. Ryan and A. Letai, BH3 profiling in whole cells by fluorimeter or FACS, Methods San Diego Calif, vol.61, pp.156-64, 2013.

G. W. Foight, J. A. Ryan, S. V. Gullá, A. Letai, and A. E. Keating, Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells, ACS Chem Biol, vol.9, pp.1962-1970, 2014.

C. Séveno, D. Loussouarn, S. Bréchet, M. Campone, and P. Juin, BarilléNion S. ?-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells, Breast Cancer Res BCR, vol.14, p.96, 2012.

D. Merino, J. R. Whittle, F. Vaillant, A. Serrano, J. Gong et al., Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer, Sci Transl Med, vol.9, 2017.

A. Young, A. Law, L. Castillo, S. Chong, H. D. Cullen et al., MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib, Breast Cancer Res BCR, vol.18, p.125, 2016.

K. J. Campbell, S. Dhayade, N. Ferrari, A. H. Sims, J. E. Mason et al., MCL-1 is a prognostic indicator and drug target in breast cancer, Cell Death Dis, vol.9, p.19, 2018.

M. Campone, B. Noël, C. Couriaud, M. Grau, Y. Guillemin et al., c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on antiapoptotic Mcl-1, Mol Cancer, vol.10, p.110, 2011.

Y. Ma, Y. Ren, Z. Dai, C. Wu, J. et al., IL-8 and TNF? levels correlate with disease stage in breast cancer patients, Adv Clin Exp Med Organ Wroclaw Med Univ, vol.26, pp.421-427, 2017.

V. Labovsky, L. M. Martinez, M. Calcagno, L. De, K. M. Davies et al., Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer, Tumour Biol J Int Soc Oncodev Biol Med, vol.37, pp.13377-84, 2016.

S. Hendrayani, A. , B. , A. -. Ansari, M. M. Silva et al., Aboussekhra A. The inflammatory/cancer-related IL-6/STAT3/NF-?B positive feedback loop includes AUF1 and maintains the active state of breast myofibroblasts, Oncotarget, vol.7, pp.41974-85, 2016.

P. Sansone, C. Ceccarelli, M. Berishaj, Q. Chang, V. K. Rajasekhar et al., Self-renewal of CD133(hi) cells by IL6/ Notch3 signalling regulates endocrine resistance in metastatic breast cancer, Nat Commun, vol.7, p.10442, 2016.

S. Carné-trécesson, D. Souazé, F. Basseville, A. Bernard, A. Pécot et al., BCL-XL directly modulates RAS signalling to favour cancer cell stemness, Nat Commun, vol.8, p.1123, 2017.

D. Lagares, A. Santos, P. E. Grasberger, F. Liu, C. K. Probst et al., Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis, Sci Transl Med, vol.9, 2017.

J. C. Mertens, C. D. Fingas, J. D. Christensen, R. L. Smoot, S. F. Bronk et al., Therapeutic effects of deleting cancerassociated fibroblasts in cholangiocarcinoma, Cancer Res, vol.73, pp.897-907, 2013.

A. Kotschy, Z. Szlavik, J. Murray, J. Davidson, A. L. Maragno et al., The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models, Nature, vol.538, pp.477-82, 2016.

A. Costa, Y. Kieffer, A. Scholer-dahirel, F. Pelon, B. Bourachot et al., Fibroblast heterogeneity and immunosuppressive environment in human breast cancer, Cancer Cell, vol.33, pp.463-479, 2018.

M. Romagnoli, V. Trichet, C. David, M. Clément, P. Moreau et al., Significant impact of survivin on myeloma cell growth, Leukemia, vol.21, pp.1070-1078, 2007.

P. Jézéquel, D. Loussouarn, C. Guérin-charbonnel, L. Campion, A. Vanier et al., Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response, Breast Cancer Res BCR, vol.17, p.43, 2015.

K. Yoshihara, M. Shahmoradgoli, E. Martínez, R. Vegesna, H. Kim et al., Inferring tumour purity and stromal and immune cell admixture from expression data, Nat Commun, vol.4, p.2612, 2013.

, Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours, Nature, vol.490, pp.61-70, 2012.